Starling Oncology, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Starling Oncology, Inc. (DFPH) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $1.41 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.41M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.12M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $717.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.43M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $1.41M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.12M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $717.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.43M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.32M 10-Q · filed 2025-05-14 |
| 2024-09-30 | $774.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.55M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $2.32M 10-Q · filed 2024-05-14 |
| 2023-09-30 | $770.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.55M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.18M 10-Q · filed 2023-05-10 |